124
Kronik HCV
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in
Egypt. Lancet 2000;355:887-891.
6.
Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral
hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat
2013;20:600-601.
7.
Mohd Hana ah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology
of hepatitis C virus infection: new estimates of age-speci c antibody to HCV
seroprevalence. Hepatology 2013;57:1333-1342.
8.
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
9.
[52 Collaborators.] Causes of death in HIV-1-infected patients treated with
antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.
Clin Infect Dis 2010;50:1387-1396.
10.
Razavi H, ElKhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic
hepatitis C virus (HCV) disease burden and cost in the United States.
HepatologyEPATOLOGY 2013;57:2164-2170.
11.
Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic
hepatitis C treatment outcomes in low- and middleincome countries: a systematic
review and meta-analysis. Bull WHO 2012;90:540-550.
12.
Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A,
et al. Expanding access to treatment for hepatitis C in resource-limited settings:
lessons from HIV/AIDS. Clin Infect Dis 2012;54:1465-1472.
13.
Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A
proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology
1994;19:1321-1324.
14.
Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of
hepatitis C virus genotypes. J Gen Virol 1997;78(Pt 2): 321-328.
15.
Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic
among injecting drug users. Infect Genet Evol 2005;5: 131-139.
16.
Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, et al. The
global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic
analysis. PLoS Med 2009;6:e1000198.
17.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E.
Global distribution and prevalence of hepatitis C virus genotypes. Hepatology.
2015 Jan;61(1):77-87.
18.
Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of
sequence analysis of the NS5B region for routine genotyping of hepatitis C virus
with reference to C/E1 and 5’ untranslated region sequences. J Clin Microbiol
2007;45:1102-1112
19.
Roman F, Hawotte K, Struck D, Ternes AM, Servais JY, Arendt V, et al. Hepatitis C
virus genotypes distribution and transmission risk factors in Luxembourg from 1991
to 2006. World J Gastroenterol 2008;14:1237-1243.
20.
Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, et al.
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J
Med Virol 2006;78:1296-1303.
21.
Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence
of chronic viral hepatitis in people of south Asian ethnicity living in England: the
prevalence cannot necessarily be predicted from the prevalence in the country of
origin. J Viral Hepat 2010;17:327-335.
22.
Mıstık R. Türkiye’de Viral hepatitlerin epidemiyolojik analizi. Editörler: Kılıçturgay K,
